Humacyte (HUMA) Other Non-Current Liabilities (2020 - 2026)

Humacyte (HUMA) has 7 years of Other Non-Current Liabilities data on file, last reported at $10.8 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $10.8 million, up 212.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.8 million (up 212.82% YoY), and the FY2025 annual result was $11.5 million, down 83.81% from the prior year.
• Other Non-Current Liabilities eased to $10.8 million in Q1 2026 per HUMA's latest filing, from $11.5 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $100.4 million in Q1 2022 and troughed at $78000.0 in Q4 2023.
• A 5-year average of $30.8 million and a median of $16.6 million in 2025 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities surged 90875.64% in 2024, then tumbled 98.55% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $257000.0 in 2022, then tumbled by 69.65% to $78000.0 in 2023, then surged by 90875.64% to $71.0 million in 2024, then tumbled by 83.81% to $11.5 million in 2025, then retreated by 5.71% to $10.8 million in 2026.
• Business Quant data shows HUMA's Other Non-Current Liabilities at $10.8 million in Q1 2026, $11.5 million in Q4 2025, and $21.8 million in Q3 2025.